Time to Think about HLA-Based Diagnostics in Lung Cancer?
- PMID: 37756560
- DOI: 10.1158/1078-0432.CCR-23-2152
Time to Think about HLA-Based Diagnostics in Lung Cancer?
Abstract
HLA evolutionary divergence reflects the ability to recognize diverse neoantigens as non-self, and as a biomarker is conceptually distinct from programmed cell death ligand 1 expression and tumor mutation burden. HLA-based assays to predict benefit from immunotherapy in lung cancer require prospective validation. See related article by Jiang et al., p. 4830.
©2023 American Association for Cancer Research.
Comment on
-
HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non-Small Cell Lung Cancer.Clin Cancer Res. 2023 Dec 1;29(23):4830-4843. doi: 10.1158/1078-0432.CCR-23-0604. Clin Cancer Res. 2023. PMID: 37449971
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
